The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population
Open accessAbstract
In a large cohort of 1034 patients with the diagnosis of definite or probable amyotrophic lateral sclerosis (ALS), the association of forced vital capacity (FVC) at baseline with (a) time to progression of 20 points in Appel ALS (AALS) score or (b) tracheostomy free survival was investigated. The median survival of ALS patients with baseline FVC <75% was 2.91 years, compared with 4.08 years for patients with baseline FVC >75% (p<0.001). Patients with baseline FVC <75% progressed more rapidly (taking 8.0 months to progress 20 AALS points) compared with patients with baseline FVC >75% (10.0 months, p<0.001). Moreover, FVC at first examination was identified as a significant predictor of survival and disease progression in both univariate and multivariate Cox regression models, after adjustment for age, sex, site of onset, diagnostic delay, riluzole therapy, and use of bilateral positive airway pressure and percutaneous endoscopic gastrostomy (p<0.001). We conclude that a single FVC value obtained at an initial visit may serve as a clinically meaningful predictor of survival and disease progression in ALS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Brooks, B. R. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90191-0 · Cited by 2,140
Haverkamp, L. J., Appel, V., & Appel, S. H. (1995) · Brain · doi:10.1093/brain/118.3.707 · Cited by 696
Bipap improves survival and rate of pulmonary function decline in patients with ALS
Kleopa, K. A., Sherman, M., Neal, B., Romano, G. J., & Heiman-Patterson, T. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00045-3 · Cited by 389
Traynor, B. J., Codd, M. B., Corr, B., Forde, C., Frost, E., & Hardiman, O. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.8.1171 · Cited by 380
Early symptom progression rate is related to ALS outcome: A prospective population-based study
Chiò, A., Mora, G., Leone, M., Mazzini, L., Cocito, D., Giordana, M. T., Bottacchi, E., & Mutani, R. (2002) · Neurology · doi:10.1212/wnl.59.1.99 · Cited by 266
Prognostic indicators of survival in ALS
Stambler, N., Charatan, M., Cedarbaum, J. M., & ALS CNTF Treatment Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.66 · Cited by 254
The ALSFRSr predicts survival time in an ALS clinic population
Kaufmann, P., Levy, G., Thompson, J. L. P., DelBene, M. L., Battista, V., Gordon, P. H., Rowland, L. P., Levin, B., & Mitsumoto, H. (2005) · Neurology · doi:10.1212/01.wnl.0000148648.38313.64 · Cited by 243
The natural history of amyotrophic lateral sclerosis
Ringel, S. P., Murphy, J. R., Alderson, M. K., Bryan, W., England, J. D., Miller, R. G., Petajan, J. H., Smith, S. A., Roelofs, R. I., Ziter, F., et al. (1993) · Neurology · doi:10.1212/wnl.43.7.1316 · Cited by 243
A rating scale for amyotrophic lateral sclerosis: Description and preliminary experience
Appel, V., Stewart, S. S., Smith, G., & Appel, S. H. (1987) · Annals of Neurology · doi:10.1002/ana.410220308 · Cited by 226
Cited by
Prognostic factors in ALS: A critical review
Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., Traynor, B. G., & On Behalf of the Eurals Consortium (2009) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960802566824 · Cited by 1,172
A comprehensive review of amyotrophic lateral sclerosis
Zarei, S., Carr, K., Reiley, L., Diaz, K., Guerra, O., Altamirano, P., Pagani, W., Lodin, D., Orozco, G., & Chinea, A. (2015) · Surgical Neurology International · doi:10.4103/2152-7806.169561 · Cited by 709
Energy metabolism in amyotrophic lateral sclerosis
Dupuis, L., Pradat, P.-F., Ludolph, A. C., & Loeffler, J.-P. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70224-6 · Cited by 537
Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues
Logroscino, G., Traynor, B. J., Hardiman, O., Chio', A., Couratier, P., Mitchell, J. D., Swingler, R. J., Beghi, E., & EURALS, F. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2006.104828 · Cited by 448
Fang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30054-1 · Cited by 259
Metadata
- Authors
- Czaplinski, A.
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2005-07-26
- Volume
- 77
- Issue
- 3
- Pages
- 390-392
- ISSN
- 0022-3050 (ISSN-L)
- OpenAlex
- W1974240968
- Cited by
- 273
- References
- 23
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. https://app.cochat.ai/papers/10.1136/jnnp.2005.072660
- The paper
- Czaplinski, A. (2005). Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. Journal of Neurology, Neurosurgery & Psychiatry. https://doi.org/10.1136/jnnp.2005.072660
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
